Eptinezumab for the treatment of migraine.

Abstract

INTRODUCTION:

Migraine is one of the most common illnesses in the world, with severe economical and subjective implications. Nowadays specific and nonspecific drugs are used for migraine chronic therapy, but a portion of patients have no benefit from these administrations. CGRP receptor antagonists are a good preventive treatment for episodic and chronic migraine.

AREAS COVERED:

This article reviews both preclinical and clinical studies on eptinezumab as a potential preventive therapy for migraine, as well as pharmacokinetic and pharmacodynamic features. Thus, it summarizes safety and tolerability data based on human studies.

EXPERT OPINION:

Eptinezumab had good results in several trials, making this molecule a promising migraine preventive drug. Although preclinical and clinical studies showed a significant efficacy, there are no data on the use of Eptinezumab during pregnancy or breastfeeding. There are still some knowledge limits about its pharmacokinetics and metabolism. This is a matter of concern that should be addressed in future studies.

• Authors: Valerio Spuntarelli, Andrea Negro, Michelangelo Luciani, Enrico Bentivegna, Paolo Martelletti
• Journal: Expert opinion on biological therapy (Expert Opin Biol Ther) Vol. 21 Issue 8 Pg. 999-1011 (08 2021) ISSN: 1744-7682 [Electronic] England
• PMID: 34009094 (Publication Type: Journal Article, Review)

Chemical References

• Antibodies, Monoclonal, Humanized
• eptinezumab
• Calcitonin Gene-Related Peptide

Topics

• Antibodies, Monoclonal, Humanized (therapeutic use)
• Calcitonin Gene-Related Peptide
• Graft vs Host Disease
• Humans
• Migraine Disorders (drug therapy, prevention & control)